Archive for the ‘dermatology retractions’ Category
Journal expresses concerns over “possible data irregularities” in paper from Army medical center docs
The Journal of the American Academy of Dermatology has issued an expression of concern about a 2012 article reporting the experience of military burn unit treating a rare ailment called toxic epidermal necrolysis.
According to the notice, which is behind a paywall (for shame!), the paper appears to have overstated the number of cases the hospital itself has treated of the life-threatening condition: Read the rest of this entry »
A Boston doctor indicted on charges of Medicare fraud in 2007 has had a paper relating to the case retracted this month.
Abdul Razzaque Ahmed was considered something of a miracle worker by his patients, treating two rare and disfiguring skin conditions called pemphigoid and pemphigus vulgaris. He used more powerful medicines than the typical course of treatment, including a drug normally used to treat cancer.
The initial indictment stated that Ahmed mixed blood samples to falsely show a “dual diagnosis” of both diseases, and prove to Medicare that they required the more rigorous (and expensive) treatment. It also alleged that he profited massively from the government pay-outs. He was convicted of obstruction in 2007; the other charges were dropped when he agreed to forfeit assets worth $2.9 million.
Now, a 2001 paper by Ahmed, which claimed fifteen patients had a dual diagnosis, has been retracted because the samples were all mixed. Here is the retraction notice from Clinical Immunology: Read the rest of this entry »
Acta Dermatovenerologica Alpina, Pannonica et Adriatica is retracting the 2009 article “Association of cytokine gene polymorphisms with psoriasis in cases from the Nile Delta of Egypt” after discovering that they were far from the first publication to print the paper.
An Australian university has put a hold on trials of an experimental drug for skin cancer whose main developer has been dogged by charges of research misconduct for several years.
The Australian Broadcasting Corporation is reporting that the University of New South Wales has suspended trials of the drug, DZ13, while it investigates the work of Levon Khachigian, who is leading the studies.
According to the news organization, Khachigian and his group were cleared by the school in two prior inquiries. However, additional accusations of misconduct — specifically involving image manipulation and misuse — prompted a third investigation.
We’ve found four retractions of Khachigian’s studies, from the Journal of Biological Chemistry and Biochemical and Biophysical Research Communications, between 2009 and 2010 (before the launch of Retraction Watch).
They are: Read the rest of this entry »
The Office of Research Integrity (ORI) has sanctioned an assistant professor of dermatology at Case Western Reserve University in Cleveland for plagiarizing from a grant application she was reviewing — which feels like a scientific version of insider trading — and a number of published papers.
A group of researchers from India and China has lost a 2012 article in the Biochemical Engineering Journal for lifting a figure from a previously published article from another team of investigators. Evidently, caught red-handed, they haven’t copped to the caper.
The article was titled “Purification and characterization of organic solvent and detergent stable protease isolated from marine Saccharopolyspora sp. A9: Application of protease for wound healing.” According to the retraction notice: Read the rest of this entry »